NU6027

Overview

NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2 , with K i s of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > ATM/ATR

Product Information

• Catalog No.: HY-13816
• CAS No.: 220036-08-8
• Molecular Formula: C11H17N5O2
• Molecular Weight: 251.28
• Purity: 98.01%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 1.25 mg/mL (4.97 mM); Clear solution
• Availability: In-stock

Source

Original product source